Search results for "Materia medica"

showing 10 items of 121 documents

Encapsulation of Alcohol Dehydrogenase in Mannitol by Spray Drying

2014

The retention of the enzyme activity of alcohol dehydrogenase (ADH) has been studied in various drying processes such as spray drying. The aim of this study is to encapsulate ADH in mannitol, either with or without additive in order to limit the thermal denaturation of the enzyme during the drying process. The retention of ADH activity was investigated at different drying temperatures. When mannitol was used, the encapsulated ADH was found inactive in all the dried powders. This is presumably due to the quick crystallization of mannitol during spray drying that resulted in the impairment of enzyme protection ability in comparison to its amorphous form. Maltodextin (dextrose equivalent = 11)…

Dextrose equivalentlcsh:RS1-441Pharmaceutical ScienceArticlelaw.inventionlcsh:Pharmacy and materia medicachemistry.chemical_compoundlawmedicinespray dryingCrystallizationAlcohol dehydrogenasechemistry.chemical_classificationChromatographybiologyChemistryalcohol dehydrogenasemannitolMaltodextrinEnzyme assayEnzymeBiochemistrySpray dryingalcohol dehydrogenase; encapsulation; spray drying; mannitolbiology.proteinencapsulationMannitolhormones hormone substitutes and hormone antagonistsmedicine.drugPharmaceutics
researchProduct

Aliskiren: Just a New Drug for Few Selected Patients or an Innovative Molecule Predestinated to Replace Arbs and Ace-Inhibitors?

2009

The renin-angiotensin-aldosterone system (RAAS) plays a dominant role in the pathophysiology of hypertension, diabetes mellitus, chronic kidney disease and chronic heart failure. Therefore, drugs that block key components of the RAAS such as ACE inhibitors (ACEI) and angiotensin receptor blockers (ARBs) have gained wide clinical use for these indications. Despite progress, the morbidity and mortality of patients treated with ACEI or ARBs remain high. Aliskiren (Tekturna, Rasilez) is the first orally active inhibitor of renin approved for clinical use as an antihypertensive agent. The development program has established that at the licensed doses of 150 mg and 300 mg. Aliskiren is effective …

DrugACE inhibitorsmedia_common.quotation_subjectPharmaceutical Sciencelcsh:Medicinelcsh:RS1-441ReviewPharmacologylcsh:Pharmacy and materia medicachemistry.chemical_compoundRAS systemDiabetes mellitusDrug DiscoveryRenin–angiotensin systemmedicinecardiovascular diseasesmedia_commonbusiness.industrylcsh:RAliskirenmedicine.diseaseangiotensin receptor blockerschemistryPathophysiology of hypertensionHeart failureMolecular MedicineAngiotensin Receptor BlockersbusinessaliskirenKidney diseasePharmaceuticals
researchProduct

Rapamycin-Loaded Polymeric Nanoparticles as an Advanced Formulation for Macrophage Targeting in Atherosclerosis

2021

Recently, rapamycin (Rapa) represents a potential drug treatment to induce regression of atherosclerotic plaques

DrugBiodistributionmedia_common.quotation_subjectPharmaceutical ScienceExcipientNanoparticlelcsh:RS1-44102 engineering and technologyPharmaceutical formulationArticlelcsh:Pharmacy and materia medica03 medical and health scienceschemistry.chemical_compoundPhosphatidylcholinemedicine030304 developmental biologymedia_commonKOdia-PC0303 health sciencesrapamycin (Rapa)technology industry and agriculture021001 nanoscience & nanotechnologyIn vitromacrophage targetingpolymeric nanoparticleschemistrySettore CHIM/09 - Farmaceutico Tecnologico ApplicativoPolycaprolactoneBiophysicsatherosclerosis0210 nano-technologymedicine.drugPharmaceutics
researchProduct

Long-Circulating Hyaluronan-Based Nanohydrogels as Carriers of Hydrophobic Drugs

2018

[EN] Nanohydrogels based on natural polymers, such as polysaccharides, are gaining interest as vehicles for therapeutic agents, as they can modify the pharmacokinetics and pharmacodynamics of the carried drugs. In this work, hyaluronan-riboflavin nanohydrogels were tested in vivo in healthy rats highlighting their lack of toxicity, even at high doses, and their different biodistribution with respect to that of native hyaluronan. They were also exploited as carriers of a hydrophobic model drug, the anti-inflammatory piroxicam, that was physically embedded within the nanohydrogels by an autoclave treatment. The nanoformulation was tested by intravenous administration showing an improvement of…

DrugBiodistributionmedia_common.quotation_subjectRiboflavinPharmaceutical Sciencelcsh:RS1-441Pharmacokinetic02 engineering and technologyPharmacologyPiroxicam030226 pharmacology & pharmacyArticleNanohydrogelsLong circulatinglcsh:Pharmacy and materia medica03 medical and health sciencesPiroxicam0302 clinical medicineBiodistributionPharmacokineticsIn vivomedicineHyaluronanbiodistribution; hyaluronan; hydrophobic drugs; nanohydrogels; pharmacokinetic; piroxicam; riboflavinmedia_commonChemistry021001 nanoscience & nanotechnologyHydrophobic drugsToxicityCirculation time0210 nano-technologymedicine.drug
researchProduct

Regional Intestinal Drug Permeability and Effects of Permeation Enhancers in Rat

2020

Sufficient colonic absorption is necessary for all systemically acting drugs in dosage forms that release the drug in the large intestine. Preclinically, colonic absorption is often investigated using the rat single-pass intestinal perfusion model. This model can determine intestinal permeability based on luminal drug disappearance, as well as the effect of permeation enhancers on drug permeability. However, it is uncertain how accurate the rat single-pass intestinal perfusion model predicts regional intestinal permeability and absorption in human. There is also a shortage of systematic in vivo investigations of the direct effect of permeation enhancers in the small and large intestine. In …

DrugKetoprofenmedia_common.quotation_subjectlcsh:RS1-441Pharmaceutical ScienceGastroenterology and Hepatology02 engineering and technologyPharmacology030226 pharmacology & pharmacyArticleDosage formlcsh:Pharmacy and materia medicaJejunumPharmaceutical Sciences03 medical and health sciences0302 clinical medicineabsorption-modifying excipientsintestinal perfusionIn vivoGastroenterologimedicineLarge intestineregional intestinal permeabilitymedia_commonIntestinal permeabilityChemistrypermeation enhancersPermeationFarmaceutiska vetenskaper021001 nanoscience & nanotechnologymedicine.diseasepharmaceutical developmentmedicine.anatomical_structureoral peptide delivery0210 nano-technologymedicine.drugPharmaceutics
researchProduct

Novo, S. et al. Aliskiren: Just a New Drug for Few Selected Patients or an Innovative Molecule Predestinated to Replace Arbs and Ace-Inhibitors? Phar…

2011

The renin-angiotensin-aldosterone system (RAAS) plays a dominant role in the pathophysiology of hypertension, diabetes mellitus, chronic kidney disease and chronic heart failure. Therefore, drugs that block key components of the RAAS such as ACE inhibitors (ACEI) and angiotensin receptor blockers (ARBs) have gained wide clinical use for these indications. Despite progress, the morbidity and mortality of patients treated with ACEI or ARBs remain high. Aliskiren (Tekturna, Rasilez) is the first orally active inhibitor of renin approved for clinical use as an antihypertensive agent. The development program has established that at the licensed doses of 150 mg and 300 mg. Aliskiren is effective …

DrugRamiprilbusiness.industrymedia_common.quotation_subjectlcsh:RPharmaceutical ScienceCorrectionlcsh:Medicinelcsh:RS1-441AliskirenPharmacologylcsh:Pharmacy and materia medicachemistry.chemical_compoundIrbesartanAliskiren 300 MGn/achemistryDrug DiscoverymedicineMolecular MedicineDosing intervalbusinessmedia_commonmedicine.drugPharmaceuticals
researchProduct

Solid and Semisolid Innovative Formulations Containing Miconazole-Loaded Solid Lipid Microparticles to Promote Drug Entrapment into the Buccal Mucosa

2021

The currently available antifungal therapy for oral candidiasis (OC) has various limita- tions restricting its clinical use, such as short retention time, suboptimal drug concentration and low patients compliance. These issues could be overcome using micro or nanotechnology. In par- ticular, solid lipid microparticles (SLMs) resulted as a particularly promising penetration enhancer carrier for lipophilic drugs, such as the antifungal miconazole (MCZ). Based on these considera- tions, cetyl decanoate (here synthesized without the use of metal catalysis) was employed together with 1-hexadecanol to prepare MCZ-loaded SLMs. These resulted in a powder composed of 45–300 µm diameter solid spheric…

Drugbuccal filmmedia_common.quotation_subjectPharmaceutical SciencemiconazoleBuccal mucosaArticleDosage formbuccal gelEntrapmentPharmacy and materia medicaoral candidiasismedicineex vivo studiemedia_commonChromatographycetyl decanoateChemistryex vivo studiesBuccal administrationPermeationoral candidiasiRS1-441mucosal deliverySettore CHIM/09 - Farmaceutico Tecnologico Applicativopenetration enhancersolid lipid microparticlebuccal mucosasolid lipid microparticlesMiconazoleEx vivomedicine.drugPharmaceutics
researchProduct

Influence of Chemical Enhancers and Iontophoresis on the In Vitro Transdermal Permeation of Propranolol: Evaluation by Dermatopharmacokinetics

2018

[EN] The aims of this study were to assess, in vitro, the possibility of administering propranolol transdermally and to evaluate the usefulness of the dermatopharmacokinetic (DPK) method in assessing the transport of drugs through stratum corneum, using propranolol as a model compound. Four chemical enhancers (decenoic and oleic acid, laurocapram, and R-(+)-limonene) and iontophoresis at two current densities, 0.25 and 0.5 mA/cm(2) were tested. R-(+)-limonene, and iontophoresis at 0.5 mA/cm(2) were proven to be the most efficient in increasing propranolol transdermal flux, both doubled the original propranolol transdermal flux. Iontophoresis was demonstrated to be superior than the chemical…

Drugdermatopharmacokineticsmedia_common.quotation_subjectChemical enhancerslcsh:RS1-441Pharmaceutical SciencePropanol - Uso terapéutico.02 engineering and technologyPropranololMedicamentos - Administración.030226 pharmacology & pharmacyArticlelcsh:Pharmacy and materia medicaIonización.03 medical and health sciences0302 clinical medicineIonization.medicineStratum corneumpropranololDermatopharmacokineticsTransdermalmedia_commonchemical enhancersChromatographytransdermal administrationIontophoresisChemistryLaurocapramTransdermal administrationIontophoresisDrugs - Administration.Skin absorption.iontophoresisPermeation021001 nanoscience & nanotechnologyPropranololPropanol - Therapeutic use.In vitromedicine.anatomical_structurePropanol - Pharmacokinetics.Propanol - Farmacocinética.Absorción cutánea.0210 nano-technologymedicine.drugPharmaceutics
researchProduct

Cyanocobalamin Ultraflexible Lipid Vesicles: Characterization and In Vitro Evaluation of Drug-Skin Depth Profiles

2021

Atopic dermatitis (AD) and psoriasis are the most common chronic inflammatory skin disorders, which importantly affect the quality of life of patients who suffer them. Among other causes, nitric oxide has been reported as part of the triggering factors in the pathogenesis of both conditions. Cyanocobalamin (vitamin B12) has shown efficacy as a nitric oxide scavenger and some clinical trials have given positive outcomes in its use for treating skin pathologies. Passive skin diffusion is possible only for drugs with low molecular weights and intermediate lipophilicity. Unfortunately, the molecular weight and hydrophilicity of vitamin B12 do not predict its effective diffusion through the skin…

Drugliposomesmedia_common.quotation_subjectPharmaceutical Sciencelcsh:RS1-441Dermatitis02 engineering and technologyPharmacology030226 pharmacology & pharmacyArticleNitric oxidelcsh:Pharmacy and materia medica03 medical and health scienceschemistry.chemical_compound0302 clinical medicinePsoriasismedicineCyanocobalaminVitamin B12cyanocobalaminskin topical deliverymedia_commonLiposomeatopic dermatitisVesiclePellAtopic dermatitisvitamin B12psoriasis021001 nanoscience & nanotechnologymedicine.diseaselipid vesicleschemistrytransferosomes0210 nano-technologyTecnologia farmacèuticaPharmaceutics
researchProduct

Induction of Drug Transporters Alters Disposition of Risperidone - A Study in Mice

2010

Pharmacokinetic interactions, e.g. modulation of drug transporters like P-glycoprotein at the blood-brain barrier, can be a reason for treatment non-response. This study focuses on the influence of induction of drug transporters on the disposition of the antipsychotic drugs risperidone and 9-hydroxyrisperidone. Brain and serum concentrations of risperidone and its active metabolite 9-hydroxyrisperidone, which are known P-glycoprotein substrates, were measured after drug transporter induction with rifampicin, dexamethasone or 5-pregnene-3beta-ol-20-on-16alpha-carbonitrile using high performance liquid chromatography. Disposition of risperidone and 9-hydroxyrisperidone was dramatically decrea…

Drugmedia_common.quotation_subjectmedicine.medical_treatmentlcsh:RS1-441Pharmaceutical ScienceP-glycoproteinPharmacologyArticlelcsh:Pharmacy and materia medicaPharmacokineticsMedicineAntipsychoticDexamethasoneActive metaboliteP-glycoproteinmedia_commonrisperidoneRisperidonebiologybusiness.industryTransporterdrug transporterantipsychoticsdispositionbiology.protein9-hydroxyrisperidonebusinessmedicine.drugPharmaceutics
researchProduct